CSIMarket
 


Lexaria Bioscience Corp   (LEXX)
Other Ticker:  
 
 

LEXX's Capital Expenditures Growth by Quarter and Year

Lexaria Bioscience 's Capital Expenditures results by quarter and year




LEXX Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter August - 0.07 0.00 0.00
III Quarter May - 0.03 0.04 0.07
II Quarter February - 0.03 0.08 0.00
I Quarter November 0.04 0.03 0.02 0.01
FY   0.04 0.16 0.14 0.08



LEXX Capital Expenditures first quarter 2023 Y/Y Growth Comment
Lexaria Bioscience Corp reported Capital Expenditures improvement of 33.42% year on year in the first quarter 2023, to $ 0.04 millions, this is lower than Lexaria Bioscience Corp 's recent average Capital Expenditures improvement of 38.88%.

According to the results reported in the first quarter 2023, Lexaria Bioscience Corp achieved the best Capital Expenditures growth in Major Pharmaceutical Preparations industry. While Lexaria Bioscience Corp ' s Capital Expenditures rise of 33.42% ranks overall at the positon no. 21 in the first quarter 2023.




LEXX Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter August - - - -
III Quarter May - -25 % -42.86 % 600 %
II Quarter February - -62.5 % - -
I Quarter November 33.42 % 50 % 100 % 0 %
FY   - 14.29 % 75 % 166.67 %

Financial Statements
Lexaria Bioscience 's first quarter 2023 Capital Expenditures $ 0.04 millions LEXX's Income Statement
Lexaria Bioscience 's first quarter 2022 Capital Expenditures $ 0.03 millions Quarterly LEXX's Income Statement
New: More LEXX's historic Capital Expenditures Growth >>


LEXX Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter August - 133.33 % - -
III Quarter May - 0 % -50 % -
II Quarter February - 0 % 300 % -
I Quarter November -42.82 % - - 0 %
FY (Year on Year)   - 14.29 % 75 % 166.67 %




Capital Expenditures first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #21

Capital Expenditures Y/Y Growth Statistics
High Average Low
800.67 % 38.88 % -95.63 %
(Aug 31 2019)   (Aug 31 2020)
Capital Expenditures first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #21
Capital Expenditures Y/Y Growth Statistics
High Average Low
800.67 % 38.88 % -95.63 %
(Aug 31 2019)   (Aug 31 2020)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Lexaria Bioscience 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1429500 % 44927.24 % -100 %
(May 31 2020)  


LEXX's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2023 Lexaria Bioscience Corp realized fall in Capital Expenditures from the fourth quarter by -42.82% to $ 0.04 millions, from $ 0.07 millions declared a quarter before.

Within Major Pharmaceutical Preparations industry Lexaria Bioscience Corp achieved highest sequential Capital Expenditures growth. While Lexaria Bioscience 's Capital Expenditures growth quarter on quarter, overall rank is 45.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #2
Overall #45
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #2
Overall #45
Capital Expenditures Q/Q Growth Statistics
High Average Low
1429500 % 44927.24 % -100 %
(May 31 2020)  


LEXX's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2023 Lexaria Bioscience Corp reported fall in Capital Expenditures from the previous quarter by -42.82% to $ 0.04 millions, from $ 0.07 millions released a quarter before.

Within Major Pharmaceutical Preparations industry Lexaria Bioscience Corp achieved highest sequential Capital Expenditures growth. While Lexaria Bioscience 's Capital Expenditures growth quarter on quarter, overall rank is 45.


Lexaria Bioscience 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Nov 30 2023)
12 Months Ending
(Aug 31 2023)
12 Months Ending
(May 31 2023)
12 Months Ending
(Feb 28 2023)
12 Months Ending
(Nov 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.17 $ 0.17 $ 0.10 $ 0.11 $ 0.15
Y / Y Capital Expenditures Growth (TTM) 16.18 % 29.03 % - - -
Year on Year Capital Expenditures Growth Overall Ranking # 134 # 766 # 0 # 0 # 0
Seqeuential Capital Expenditures Change (TTM) 3.06 % 66.24 % -4.05 % -29.32 % 14.46 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 208 # 1039 # 28 # 47 # 21




Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Nov 30 2023 period, Lexaria Bioscience 's cumulative twelve months Capital Expenditures were $ 0 millions, company would post below average annual Capital Expenditures growth of 14.46% year on year, if the fiscal year would end at Nov 30 2023.
A slow-down in the Lexaria Bioscience 's Capital Expenditures growth from the 0.07% growth in Aug 31 2023.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 134, from total ranking in previous quarter at 766.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
800.67 %
38.88 %
-95.63 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 8
Healthcare Sector # 12
Overall # 134

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
800.67 %
38.88 %
-95.63 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 20
S&P 500 # 208
Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Nov 30 2023 period, Lexaria Bioscience 's cumulative twelve months Capital Expenditures were $ 0 millions, company would post below average annual Capital Expenditures growth of -95.63% year on year, if the fiscal year would end at Nov 30 2023.
A slow-down in the Lexaria Bioscience 's Capital Expenditures growth from the 0.07% growth in Aug 31 2023.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 134, from total ranking in previous quarter at 766.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
800.67 %
38.88 %
-95.63 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 8
Healthcare Sector # 12
Overall # 134

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
800.67 %
38.88 %
-95.63 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 20
S&P 500 # 208




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
LEXX's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for LEXX's Competitors
Capital Expenditures Growth for Lexaria Bioscience 's Suppliers
Capital Expenditures Growth for LEXX's Customers

You may also want to know
LEXX's Annual Growth Rates LEXX's Profitability Ratios LEXX's Asset Turnover Ratio LEXX's Dividend Growth
LEXX's Roe LEXX's Valuation Ratios LEXX's Financial Strength Ratios LEXX's Dividend Payout Ratio
LEXX's Roa LEXX's Inventory Turnover Ratio LEXX's Growth Rates LEXX's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Nov 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Nov 30 2023




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com